This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Results of the Early Manifest Glaucoma Trial

Arch Ophthalmol. 2002;120:1371-1372.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

PHYSICIANS REGULARLY look for indications of the best practices so that they can appropriately advise and treat their patients. Readers of this month's ARCHIVES will have considerable interest in the first results from the Early Manifest Glaucoma Trial¹ (EMGT), a National Eye Institute (NEI)–sponsored study to determine whether patients with newly diagnosed glaucoma can benefit from treatment that reduces their intraocular pressure (IOP). The EMGT may be the only clinical trial for glaucoma that will ever include an untreated study arm of patients known to have the disease. Although some readers may wonder whether it was ethical not to treat a patient with glaucomatous damage, the study was carefully designed so that untreated patients who showed the earliest progression of the disease were immediately offered treatment. Thus, no patients were allowed to lose a significant amount of visual field while going untreated.

Other investigators may ask why this study was . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
Anders Heijl, M. Cristina Leske, Bo Bengtsson, Leslie Hyman, Boel Bengtsson, Mohamed Hussein, and for the Early Manifest Glaucoma Trial Group
Arch Ophthalmol. 2002;120(10):1268-1279.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4
Williams et al.
Br J Ophthalmol 2008;92:1387-1392.
ABSTRACT | FULL TEXT  

Impact of Intraocular Pressure Reduction on Glaucoma Progression
Lichter
JAMA 2002;288:2607-2608.
FULL TEXT